biostudies-literatureUnknown16(5)Nadasdi ARamgen Plc.<b>Aim:</b> To investigate the serum circulating DPP4 activity in patients with COVID-19 disease. <b>Materials & methods:</b> Serum samples from 102 hospitalized COVID-19 patients and 43 post-COVID-19 plasma donors and 39 SARS-CoV-2 naive controls and their medical data were used. Circulating DPP4 activities according to different COVID-19 disease peak severity (WHO) groups at sampling and at peak were assessed. <b>Results:</b> A significant decrease (p < 0.0001) in serum DPP4 activity was found in study groups of higher disease severity. When the circulating DPP4 activity was assessed as a prognostic marker, the logistic regression (p = 0.0023) indicated that the enzyme activity is a predictor of mortality (median 9.5 days before death) with receiver operating characteristic area under thBiomarkers in medicine317-330https://www.ebi.ac.uk/biostudies/studies/S-EPMC8961475biostudies-literatureDecreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients.PMC8961475Firneisz GFerdinandy PForhecz ZCseh GProhaszka ZZReti MMerkely BProhaszka ZNadasdi ASinkovits GArato MValyi-Nagy ILakatos BMasszi TBobek IfalseDecreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients.<b>Aim:</b> To investigate the serum circulating DPP4 activity in patients with COVID-19 disease. <b>Materials & methods:</b> Serum samples from 102 hospitalized COVID-19 patients and 43 post-COVID-19 plasma donors and 39 SARS-CoV-2 naive controls and their medical data were used. Circulating DPP4 activities according to different COVID-19 disease peak severity (WHO) groups at sampling and at peak were assessed. <b>Results:</b> A significant decrease (p < 0.0001) in serum DPP4 activity was found in study groups of higher disease severity. When the circulating DPP4 activity was assessed as a prognostic marker, the logistic regression (p = 0.0023) indicated that the enzyme activity is a predictor of mortality (median 9.5 days before death) with receiver operating characteristic area under th2022-01-01T00:00:00Z2022 Apr2026-05-31T18:01:04.299Z2025-04-05T22:21:18.16ZS-EPMC89614753519502310.2217/bmm-2021-0717